Monday, September 21, 2026

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

“Palisade and Telluride HEVs Rival Luxury SUVs”: U.S. Auto Media Praises Hyundai and Kia

CarBuzz says Hyundai, Kia, and Genesis are rapidly narrowing the product gap with German and other luxury brands, citing the Palisade and Telluride hybrids as examples.

Nikola Stock Bounces Back with 10% Surge After Previous Day’s 9% Drop

Nikola's stock surged over 10% after a sharp decline, driven by bargain hunters amid ongoing bankruptcy speculation.

Jin Joong Hwang

Author's Latest

Revolutionizing Kidney Stone Surgery: Roen Surgical’s AI Robot Zamenix Launches in Indonesia

Roen Surgical exports AI-powered kidney stone surgery robot Zamenix to Indonesia, enhancing surgical precision and safety in healthcare.

SK Biofarm, FDA Approved Radioactive Method: Will it be a Revolutionary Cancer Cure with SLK 33501?

SK Biopharmaceuticals gains FDA approval for Phase 1 trials of radiopharmaceuticals SKL35501 and SKL35502, advancing cancer treatment.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Lotte Biologics Unveils Dual-Site Strategy: A Game Changer for Global CDMO in 2027

Lotte Biologics aims to lead in the evolving biotech landscape with dual sites in the U.S. and South Korea, enhancing global supply chains.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

The Next Trillion-Dollar Bet: Korean Pharma Invests in Immuno-Oncology, Targeting a $1 Trillion Global Market

Cho Yong-joon outlines Dongkoo Bio's transformation into a global healthcare leader, emphasizing convergence and innovative growth strategies.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

UK Pours Billions Into Health Tech to Become a Life Sciences Superpower

The UK government aims to lead Europe's life sciences by 2030, investing heavily in health data and regulatory reforms to boost growth.

New Hope for Solid Tumors? Korean Biotech Starts Phase 1 Trial of Targeted Drug

Digmbio secures 12 billion KRW for clinical trials of cancer drug DM5167 and advances treatment for degenerative brain diseases.

AI Search on Safari: Apple Confirms It’s Exploring ChatGPT and Perplexity

Apple is considering integrating AI search engines into Safari, but Google remains the default due to a lucrative contract.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.